Earnings Review and Free Research Report: DelMar Missed Earnings - Erie News Now | WICU & WSEE in Erie, PA

Earnings Review and Free Research Report: DelMar Missed Earnings Expectations

Posted: Updated:

Research Desk Line-up: XTL Biopharma Post Earnings Coverage

LONDON, UK / ACCESSWIRE / October 5, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar”), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=DMPI, following the Company’s posting of its financial results on September 28, 2017, for the fiscal year 2017. The biopharmaceutical Company’s working capital increased 15.4% on a y-o-y basis. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Biotechnology industry. Pro-TD has currently selected XTL Biopharmaceuticals Ltd (NASDAQ: XTLB) for due-diligence and potential coverage as the Company announced on September 26, 2017, its financial results for Q2 which ended on June 30, 2017 and also provided an update on the development program for its lead drug candidate hCDR1. Register for a free membership today, and be among the early birds that get access to our report on XTL Biopharma when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on DMPI; also brushing on XTLB. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=DMPI

http://protraderdaily.com/optin/?symbol=XTLB

Earnings Reviewed

During FY17, DelMar’s R&D expenses increased 48.8% to $5.00 million from $3.36 million in FY16. During FY17, DelMar’s adjusted R&D expenses increased 73.1% to $4.90 million from $2.83 million in FY16, primarily due to an increase in clinical costs related to the initiation of the STAR-3 trial, preclinical research, intellectual property, and personnel costs.

For FY17, DelMar’s G&A expenses increased 16.4% to $3.32 million from $2.85 million in FY16. During FY17, the Company’s adjusted G&A expenses increased 21% to $2.65 million from $2.19 million in FY16, attributable to an increase in professional fees, office and sundry, and personnel costs.

During FY17, DelMar’s net loss was $8.87 million compared to a net loss of $9.10 million in FY16. For the reported quarter, DelMar’s diluted earnings per share (EPS) was negative $0.74 compared to a negative diluted EPS of $0.83 in FY16. The Company’s net loss was wider than Wall Street’s expectations for a loss of $0.67 per share.

Operational Updates

As of June 30, 2017, DelMar had eight issued US patents and eight issued patents outside of the US.

In July 2017, the Company initiated patient recruitment for the STAR-3 Phase-3 clinical trial of VAL-083 in refractory GBM and expected to enroll a first patient.

In September 2017, the Company received an allowance notice from the US Food and Drug Administration (FDA) for Phases-1 and -2 VAL-083 REPROVe clinical trial in Pt-resistant ovarian cancer. The Company will seek to initiate the REPROVe trial as soon as practicable, subject to negotiating acceptable clinical research agreements and budgets with clinical investigators and their institutions, and obtaining IRB approvals.

During FY17, the Company appointed Saiid Zarrabian to its Board of Directors, and Dr. Erich Mohr as an Independent Chairman.

Balance Sheet

As on June 30, 2017, DelMar’s cash and cash equivalents increased 6.9% to $6.59 million from $6.16 million in FY16.

During FY17, the Company’s working capital increased 15.4% to $6.57 million from $5.69 million in FY16.

During FY17, the Company’s total assets increased 24.3% to $7.91 million from $6.36 million in FY16.

During FY17, the Company’s accounts payable and accrued liabilities increased 102% to $1.18 million from $584,002 in FY16.

During FY17, the Company’s cash provided by operating activities was negative $8.02 million compared to negative $5.15 million in FY16.

In April and September 2017, DelMar completed offerings of common stock and warrants for aggregate gross proceeds of approximately $19.0 million. The Company intends to use the net proceeds of these offerings for its clinical trials and general corporate purposes, which may include working capital, capital expenditures, research and development, and other commercial expenditures.

Stock Performance

On Wednesday, October 04, 2017, DelMar Pharma’s stock closed the trading session at $0.89, slightly falling 0.84% from its previous closing price of $0.90. A total volume of 730.51 thousand shares were exchanged during the session. The stock currently has a market cap of $19.34 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 477162

Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

Powered by Frankly
3514 State St. Erie, PA 16508
Newsroom: (814) 454-8812
Business offices: (814) 454-5201
WICU FCC Filing
WSEE FCC Filing
Share:
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
RSS Feeds
All content © Copyright 2000 - 2017 WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 - info@wicu12.com